EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis

Jiayang Lin, Yan Huang, Bingyan Xu, Chensihan Huang, Fei Teng, Youwen Yuan, Jinhua Zhang, Huijie Zhang iD

Journal of Diabetes · 2026

DOI: 10.1111/1753-0407.70206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes, 2026. Verfasst von Jiayang Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Sodium-Glucose Transporter 2 Inhibitors, Fatty Liver, Metabolic Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Science Fund for Distinguished Young Scholars, Guangzhou Science and Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MASH denotes metabolic dysfunction-associated steatohepatitis. MASH improvement was defined as a decrease in the non-alcoholic fatty liver disease activity score (NAS) of ≥ 2 points or NAS ≤ 3 at week 48 after treatment, with no worsening of fibrosis (i.e., no increase in fibrosis stage). MASH resolution was defined as a hepatocellular ballooning score of 0 and a lobular inflammation score of 0 or 1 at week 48, with no worsening of fibrosis. Fibrosis improvement was defined as a reduction in fibrosis of ≥ 1 stage at week 48, with no worsening of MASH (i.e., no increase in steatosis, ballooning, or inflammation scores).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseSodium-Glucose Transporter 2 InhibitorsFatty LiverMetabolic DiseasesHumansLiver Cirrhosis

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • School of Public Health, Southern Medical University, Guangzhou, China.
  • Key Laboratory of Functional and Clinical Translational Medicine, Department of General Medicine, Xiamen Medical College, Xiamen, China.
  • Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Huijie Zhang

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • National Science Fund for Distinguished Young Scholars
  • Guangzhou Science and Technology Plan Project
  • Xiamen Municipal Medical and Health Science and Technology Program
  • Fujian Provincial Natural Science Foundation of China
  • National Natural Science Foundation of China
  • Joint Funds of the National Natural Science Foundation of China

Zitieren

APA

Lin, J., Huang, Y., Xu, B., Huang, C., Teng, F., Yuan, Y., Zhang, J., & Zhang, H. (2026). Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis. Journal of Diabetes. https://doi.org/10.1111/1753-0407.70206

Vancouver

Lin J, Huang Y, Xu B, Huang C, Teng F, Yuan Y, et al. Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis. Journal of Diabetes. 2026. doi:10.1111/1753-0407.70206

BibTeX
@article{Lin2026,
  author = {Lin, Jiayang and Huang, Yan and Xu, Bingyan and Huang, Chensihan and Teng, Fei and Yuan, Youwen and Zhang, Jinhua and Zhang, Huijie},
  title = {Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis},
  journal = {Journal of Diabetes},
  year = {2026},
  doi = {10.1111/1753-0407.70206}
}
Kostenlos starten →